These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 37861363)
21. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants. Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008 [TBL] [Abstract][Full Text] [Related]
22. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation. Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366 [TBL] [Abstract][Full Text] [Related]
23. Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis. McGarry JL; Creavin B; Kelly ME; Gallagher TK J Surg Oncol; 2022 Nov; 126(6):1028-1037. PubMed ID: 35770919 [TBL] [Abstract][Full Text] [Related]
24. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001 [TBL] [Abstract][Full Text] [Related]
25. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA; Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806 [TBL] [Abstract][Full Text] [Related]
26. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Karloski E; Dudley B; Diergaarde B; Blanco A; Everett JN; Levinson E; Rangarajan T; Stanich PP; Childers K; Brown S; Drogan C; Cavestro GM; Gordon K; Singh A; Simeone DM; Reich H; Kastrinos F; Zakalik D; Hampel H; Pearlman R; Gordon OK; Kupfer SS; Puzzono M; Zuppardo RA; Brand RE Cancer; 2024 Oct; 130(19):3297-3304. PubMed ID: 38809542 [TBL] [Abstract][Full Text] [Related]
27. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839 [TBL] [Abstract][Full Text] [Related]
28. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556 [TBL] [Abstract][Full Text] [Related]
29. Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors. Chittenden A; Haraldsdottir S; Chen E; Nissim S Hematol Oncol Clin North Am; 2022 Oct; 36(5):943-960. PubMed ID: 36265992 [TBL] [Abstract][Full Text] [Related]
30. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499 [TBL] [Abstract][Full Text] [Related]
31. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. Astiazaran-Symonds E; Goldstein AM J Gastroenterol; 2021 Aug; 56(8):713-721. PubMed ID: 34255164 [TBL] [Abstract][Full Text] [Related]
32. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ; Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756 [TBL] [Abstract][Full Text] [Related]
33. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer. Konings IC; Harinck F; Poley JW; Aalfs CM; van Rens A; Krak NC; Wagner A; Nio CY; Sijmons RH; van Dullemen HM; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ; Pancreas; 2017 Jan; 46(1):28-34. PubMed ID: 27846136 [TBL] [Abstract][Full Text] [Related]
34. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Peretti U; Cavaliere A; Niger M; Tortora G; Di Marco MC; Rodriquenz MG; Centonze F; Rapposelli IG; Giordano G; De Vita F; Stuppia L; Avallone A; Ratti M; Paratore C; Forti LG; Orsi G; Valente MM; Gaule M; Macchini M; Carrera P; Calzavara S; Simbolo M; Melisi D; De Braud F; Salvatore L; De Lorenzo S; Chiarazzo C; Falconi M; Cascinu S; Milella M; Reni M ESMO Open; 2021 Feb; 6(1):100032. PubMed ID: 33399070 [TBL] [Abstract][Full Text] [Related]
35. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F; Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800 [TBL] [Abstract][Full Text] [Related]
36. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400 [TBL] [Abstract][Full Text] [Related]
37. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595 [TBL] [Abstract][Full Text] [Related]
38. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584 [TBL] [Abstract][Full Text] [Related]
40. Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant. Shah I; Silva-Santisteban A; Germansky KA; Wadhwa V; Tung N; Huang DC; Kandasamy C; Mlabasati J; Bilal M; Sawhney MS J Clin Gastroenterol; 2023 Mar; 57(3):317-323. PubMed ID: 35220378 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]